Press Release

Aspen Neuroscience Announces $147.5 Million Series B Financing, Led by GV, LYFE Capital and Revelation Partners

Aspen Neuroscience Launches First Patient Screening Study for Planned Clinical Trial of Personalized Cell Replacement in Parkinson’s Disease

ProJenX Announces First Person Dosed in Phase 1 Study of Prosetin

ProJenX launches to advance novel, targeted therapies for ALS and other brain diseases

Immunitas Therapeutics Names Amanda Wagner as CEO

Immunitas Therapeutics Appoints Seng-Lai ‘Thomas’ Tan, Ph.D. as Chief Scientific Officer

Immunitas Therapeutics Completes $58 Million Series B Financing to Advance Pipeline into the Clinic and Expand Single Cell Analysis Drug Development Platform for Immuno-Oncology and Other Diseases